Vaccines R&D-2017 Featured Speakers
John Robert Coleman, Codagenix, Inc., USA
Hira L. Nakhasi, Food and Drug Administration (FDA), USA
Robert Hopkins, Emergent BioSolutions Inc, USA
Title: Development of Anthrax Vaccines for Post-Exposure Prophylaxis using FDA’s Animal Rule
Michael J Lacy, Emergent BioSolutions Inc, USA
Steven Singer, Georgetown University, USA
Title: Immune Responses to Giardia Infection
Shahin Gharakhanian, Cambridge Innovation Center, USA
Title: Critical review of Therapeutic Vaccines for the functional cure of the HIV Infection: lessons learned within clinical development programs, 2011-2017
Siba K. Samal, University of Maryland, USA
Armando Zuniga, Virometix AG, Switzerland
Rocky Cranenburgh, Prokarium, UK
Title: Development of an oral, thermo-stable vaccine for plague using the Vaxonella platform
Esther Wenzel, Technische Universität Braunschweig, Germany
Title: Fighting Pathogens and Toxins with human and human-like recombinant Antibodies
Alessandro Sette, La Jolla Institute for Allergy and Immunology, USA
Farshad Guirakhoo, GeoVax, Inc., USA
Giulio Philip Tarro, Fondazione de Beaumont Bonelli per le ricerche sul cancro, Italy
Filip Dubovsky, MedImmune USA
Nora Dellepiane, Serum Institute of India, Switzerland
Title: Challenges for vaccine regulation
Stephen Albert Johnston, The Biodesign Institute ASU, USA
Ann M. Ginsberg, AERAS, USA
Title: Turning a Corner? Progress in Tuberculosis (TB) Vaccine Development
Samuel Bogoch, Replikins, Ltd., USA
Vidadi Yusibov, University of Delaware, USA
Marjorie Robert-Guroff, National Cancer Institute, USA
Barbara K. Felber, National Cancer Institute, USA
Ravi A. Madan, National Cancer Institute, USA
Kwong Y Tsang, National Cancer Institute, USA
Title: Studies of a novel combination of recombinant adenovirus vaccines containing CEA, MUC1 or Brachyura epitopes as an immunotherapyeutic
Yvonne Saenger, New York Presbyterian Hospital, USA
Title: Immune Biomarker in Early Stage Melanoma
James E. Galen, University of Maryland School of Medicine, USA
Laurent M. Humeau, Inovio Pharmaceuticals, USA
Title: Advances in DNA Vaccine Developments
Tong-Ming Fu, Merck, USA
Osama Rahma, Dana-Farber Cancer Institute, USA
Title: Cancer vaccine development
Sophie Barreteau, VitamFero SA, French
Gustavo Moreira, Technische Universität Braunschweig, Germany
Title: A vaccine pipeline: phage display for identification of vaccine candidates, and for generation of human antibodies for diagnostics and therapy
George N. Pavlakis, National Cancer Institute, USA
Christopher Heery, National Cancer Institute, USA
Edmund J. Gosselin, Albany Medical College, USA
Title: Adjuvant-Independent Intranasal Vaccination Via Human FcgmmaRI-Targeted Fusion Protein
Kristina De Paris, UNC at Chapel Hill, USA
Title: The road to a pediatric HIV vaccine
Ali I. Fattom, NanoBio, USA
Hong Shen, Elsa Biologics, USA
Shiladitya DasSarma, University of Maryland School of Medicine, USA
Title: Antigen display and therapeutic potential of a buoyant VLP-like nanoparticle
Fusataka Koide, Southern Research, USA
Title: Emerging and Re-emerging Mosquito-Borne Infectious Diseases – The Role of Non-human Primate Models in Vaccine Development
James L. Gulley, National Cancer Institute, USA
Gunnveig Grødeland, University of Oslo and Oslo University Hospital, Norway
Title: APC-targeting of antigen for increased efficacy of vaccination
James Moon, University of University of Michigan, USA
Title: Nanodisc platform for personalized neo-antigen vaccination
Mario Skiadopoulos, Emergent Biosolutions, USA
Title: Comparative Analysis of the Antibody Threshold of Protection for the Licensed Biothrax Anthrax Vaccine and Other Novel Anthrax Vaccine Candidates
Joost J. Oppenheim, National Cancer Institute, USA
Title: TLR ligands as anti tumor vaccines in mice
Malabi M Venkatesan, Walter Reed Army Institute of Research (WRAIR), USA
Title: WRAIR's Shigella vaccine development
Ahmed Bouzidi, Vaxeal Group, Switzerland
Title: Pre-Clinical Development Of SVX-1 : A Novel Therapeutic Cancer Vaccine
Jean Marie Andrieu, Descartes University, Paris
Barbara Ensoli, Istituto Superiore di Sanità, Italy
Ruth Ruprecht, Texas Biomedical Research Institute, USA
Jay Bream, Johns Hopkins University, USA
Cyril Gerard Gay, USDA/ARS, USA
Title: Veterinary vaccine research in support of biodefense and the threat of biological threat agents
Mei Cong, Promega Corp, USA
Title: Reporter Bioassay and Vaccine Development
Klaus Überla, University Hospital Erlangen, Virology Institute, Germany
Title: Blocking HIV infection of the first cell in non-human primates by passive immunization
Moriya Tsuji, Aaron Diamond AIDS Research Center, Rockefeller Univ, USA
Spyros Kalams, Vanderbilt University Medical Center, USA
Teri Heiland, Immunomic Therapeutics, USA
Nicolas Çuburu, National Cancer Institute, USA
Title: Adenovirus vector-based prime-boost vaccination via heterologous routes induces cervicovaginal CD8+ T cell responses against HPV16 oncoproteins
Jasmin Leshem, National Cancer Institute, USA
Title: Combining Local Immunotoxins Targeting Mesothelin with CTLA-4 Blockade Eradicates Murine Cancer by Promoting Anti-Cancer Immunity
Mahin Khatami, National Cancer Institute (retired), USA
Title: Analyses of Data on Pathogen-Specific Vaccines: Weakening or Promoting Immunity?
Wendy Watford, University of Georgia, USA
Title: Induction of IFN-lambda production and anti-viral activity by the serine-threonine kinase, Tpl2: implications for influenza vaccine development
Ewan Plant, US Food & Drug Administration, USA
Title: How the annual influenza vaccination affects the antibody response to drifted viruses
Leonardo Marino-Ramirez, NIH/NLM/NCBI, USA
Title: Developing Vaccines in the Genomics Era
Andrea Facciabene, University of Pennsylvania, USA
Title: PD-1/PD-L1 antagonism increase efficacy of mitochondria based vaccine
Teresa de los Santos, ARS, USDA, USA
Title: FMD vaccines in the veterinary vaccine section
Amy Rosenberg, US Food & Drug Administration, USA
Title: Rescue of T cell Mediated Vaccine Immunity following Sublethal Irradiation
Scot Roberts, Altimmune, Inc., USA
Jerald Sadoff, Janssen Vaccines & Prevention B.V., The Netherlands
Konstantin Virnik, FDA/CBER, USA
Mariola Fotin-Mleczek, CureVac AG, Germany
Michael A. Egan, Profectus Biosciences, Inc., USA
Title: Development of the VesiculoVax™-vectored Vaccine Platform to Rapidly Respond to New Epidemic Diseases
Ashley Birkett, PATH Malaria Vaccine Initiative (MVI), USA
Elisa Scarselli,Nouscom Srl, Italy
Purnima Dubey, Wake Forest University Health Sciences, USA
Title: Reshaping acellular pertussis vaccine-induced immune responses by the novel adjuvant, BcfA
Paul Keller, FDA - CBER, USA
Andrea L. Cox, Johns Hopkins University, USA
Title: How close are we to realizing a hepatitis C vaccine- and do we need one?
Adan Rios, University of Texas Medical School in Houston, USA
Richard Wyatt, Scripps Institute in La Jolla, CA, USA
Graham Pawelec, University of Tuebingen, Germany
Title: Immune frailty: role of viral infection and impact on vaccination in the elderly
Yongjun Sui, National Cancer Institute, USA
Title: Orally delivered mucosal vaccine targeting colorectal immunity protected SHIV transmission in macaques
Klaus Schwamborn, Valneva, France
Title: Responding to the threat of emergent infectious diseases
Yoshikazu Kurosawa, Fujita Health University, Japan
Title: Analysis of antibody repertoires induced by vaccination with four kinds of H5N1 viruses in twenty volunteers
Laura Hong, Merck, USA
Title: Pivotol role of cellular necrosis in residual cytotoxicity of a recombinant vaccine against Clostridium Difficile
Danushka Kumara Wijesundara, The University of Adelaide, Australia
Title: Cytolytic DNA vaccine to induce antigen cross-presentation by dendritic cells and liver tissue resident memory CD8+ T cells
Adan Rios, The George McGovern Medical School at Houston Texas, USA
Title: Fundamental challenges to the development of an HIV vaccine
Mark C. Poznansky, Harvard Medical School, USA
Title: Accelerated development of a T cell based vaccine for Q Fever
J. Brian Kimble, University of Texas Medical Branch, USA
Title: Deconvolution of neutralizing antibody response induced by a trivalent parainfluenza-vectored ebolavirus vaccine
Murillo Silva, Northeastern University, USA
Title: Elimination of immunodominant B cells drives the germinal center reaction toward subdominant epitopes: A potential vaccination strategy to target broadly neutralizing epitopes
Guoquan Zhang, University of Missouri-Columbia, USA
Title: Development of a lipopolysaccharide targeted mimotope vaccine against Q fever
Thomas Kieber-Emmons, University of Arkansas for Medical Sciences, USA
Title: Targeting Tumor Associated Carbohydrate Antigens for Cancer Therapy
Peter Johannes Holst, University of Copenhagen, Center of Medical Parasitology, ISIM, Denmark
Title: Mucosal vaccination with accessory antigens provides surprisingly robust protection against early SIV replication. Underappreciated role of location and immunodominance in vaccination against chronic infection?
Trudy G Morrison, University of Massachusetts Medical School, USA
Title: The Importance of RSV F Protein Conformation In Stimulation of Neutralizing Antibodies in Mice Previously Infected with RSV
Franklin R. Toapanta, Universityf of Maryland, USA
Title: T cell-mediated immune responses induced by the oral live-attenuated Shigella vaccine candidate CVD 1208S in humans
Randa Hamadeh, Ministry of Public Health, Lebanon
Title: Polio update in the Middle East
Adan Rios, The George McGovern Medical School at Houston Texas, USA
J. Patricia Dhar, Wayne State University School of Medicine, USA
Title: The safety and immunogenicity of Quadrivalent HPV (qHPV) vaccine in systemic lupus erythematosus
Rachel J Stephenson, The University of Queensland, Australia
Title: Systematic evaluation of self-assembling and self-adjuvanting lipopeptide vaccine candidates for the induction of protective immune responses
Matthew Woodling, Merck & Co., Inc, USA
Title: Overcoming Bioprocess Research and Development Hurdles to Advance an LVV Candidate for Human Cytomegalovirus
Gordon Harkiss, MV Diagnostics Ltd, UK
Title: Immune responses to Mycobacterium bovis in naturally infected ruminants
Jessica A. White, PATH, USA
Title: Stability improvements to subunit and live attenuated influenza vaccines
Shengqing Yu, Chinese Academy of Agricultural Sciences, China
Title: Characterization and cross-protection evaluation of M949_1603 gene deletion Riemerella anatipestifer mutant RA-M1
Ling Chen, Guangzhou Medical University, China
Title: A HIV vaccine based on MTVV prime Adv boost controlled viral reservoir and conferred long-term protection from SIVmac239 infection
Yuetsu Tanaka, University of the Ryukyus, Japan
Title: Toward developing antibody-drugs for prophylaxis of HTLV-I infection and onset of Adult T-cell Leukemia (ATL)
James J. Moon, University of Michigan, USA
Title: Nano-vaccine platform technology for personalized cancer vaccination
Title: Initial and long-term stability study of Pfs230-EPA conjugates adjuvanted with Alhydrogel®
Yanmin Wan, Nebraska Center for Virology, USA
Title: Resident humoral response elicited by repeatedly same site inoculations inhibits systemic immunity of gene based vaccines
Yasuhiro Yasutomi, Tsukuba Primate Research Center, Japan
Title: Recombinant BCG expressing SOCS1 antagonist as a novel BCG vaccine
Jianping Li, University of Connecticut, USA
Title: Novel Universal Nanoparticle Vaccines for Bird Flu and Coronavirus Infections in Birds
Jasmin Leshem, National Cancer Institute, USA
Title: Combining Local Immunotoxins Targeting Mesothelin with CTLA-4 Blockade Synergistically Eradicates Murine Cancer by Promoting Anti-Cancer Immunity
Pierre A. MORGON, MRGN Advisors, Switzerland
Title: Successfully activating positive behaviors of the stakeholders involved in vaccine purchasing and usage through technological advances
Michael G. Hanna, Vaccinogen Inc., USA
Title: A key to the backdoor into the castle: The clinical ramifications of immunoediting driven by antigenic competition
Roy Curtiss III, University of Florida, USA
Title: Vaccine design to safely induce protective immunity of long duration
Xuejuan Bai, Army Tuberculosis Prevention and Control Key Laboratory, China
Title: Novel epitopes identified from Mycobacterium tuberculosis antigen Rv2629 could induce cytotoxic T lymphocyte response
Bernadette Ferraro, Inovio Pharmaceuticals, Inc., USA
Title: Synthetic Immunogens Drive Potent Antigen Specific Anti-Tumor Immune Responses
Jagannadha Sastry, The MD Anderson Cancer Center, Houston, TX
Title: Curative efficacy of therapeutic mucosal HPV E6/E7 peptide vaccination combined with checkpoint modulation in preclinical mouse models of HPV+ genital and oral cancers
Jonathan Abraham, Brigham & Women's Hospital/Harvard Medical School, USA
Jay A. Berzofsky, National Cancer Institute, USA
Title: Translation of cancer vaccines from mice to human clinical trials
Betsy C. Herold, Albert Einstein College of Medicine, USA
Title: Herpes Simplex Virus (HSV) DgD-2 Vaccine Elicits High Titer FcgR Activating Antibodies and Prevents Primary Infection and Latency in Multiple Small Animal Models
Stephanie M. Dorta-Estremera, MD Anderson Cancer Center, USA
Title: Enhancing the therapeutic efficacy of mucosal HPV E6/E7 peptide vaccination with checkpoint modulation in preclinical mouse models of HPV+ oral cancers
Shi-Hua Xiang, University of Nebraska-Lincoln, USA
Title: Stabilization of gp120 outer domain for HIV vaccine immunogen design
Isabel Yee Pinn Tsin, Sunway University, Malaysia
Title: Characterization of significant molecular determinants of virulence of Enterovirus 71 sub-genotype B4 in Rhabdomyosarcoma cells
Christine E. Ferragine, Biologics Resources LLC, USA
Title: Conjugate rPA-PGA anthrax vaccine induces protective antibodies
Tracy Scott, Pfizer, Inc., USA
Title: Process development of a glycoconjugate vaccine
Lihua Wang, Kansas State University, USA
Title: Recombinant porcine reproductive and respiratory syndrome virus strain P129 expressing CSFV E2 glycoprotein enhanced pathogenesis of CSFV in pigs
Rachel Madera, Kansas State University, USA
Title: Development of a one-dose classical swine fever sub-unit vaccine
Yulia Burakova, Kansas State University, USA
Title: Combination adjuvants in subunit veterinary vaccines
Jean Boyer, Inovio Pharmaceuticals, USA
Title: Systems and standard immunology demonstrated a prophylactic intradermal delivery of INO-4201 drives robust Ebola glycoprotein specific humoral and cellular immune responses in healthy volunteers in an open label phase I trial
Maryann Giel-Moloney, Sanofi Pasteur, USA
Title: A split, inactivated influenza virus vaccine containing an engineered H5 hemagglutinin elicits broadly protective antibodies
Tom H. Jin, IDT Biologika, USA
Title: Age to end dreadful diseases (HIV, Malaria, TB, cancer and more): A theory of Intact or Protected Complement (IPC) immunity
Constantinos Petrovas, Vaccine Research Center, NIAID, NIH, USA
Title: Imaging of germinal center immune dynamics: Applications in vaccine development
Mark T. Esser, MedImmune, USA
Title: Pre-vaccination baseline levels of F-specific IgG and palivizumab epitope-specific antibodies predicted vaccine efficacy and failure
Madhu Gupta, Post Graduate Institute of Medical Education and Research, India
Title: Seroprevalence of measles among children aged 5-10 years in Chandigarh, North India
Mark Tomai, 3M Drug Delivery Systems, USA
Title: 3M’s hollow microneedle system and toll-like receptor 7/8 agonist 3M-052 for enhancing vaccine effectiveness
Li Shi, Shanghai Zerun Biotechnology Co .,Ltd., China
Title: Vaccine research and development in china: Status of product development and regulatory land scope
Anuj Sharma, Uniformed Services University of the Health Sciences, USA
Title: Novel inactivated-alphavirus vaccine candidates
Jennifer A. Schwartz, Profectus BioSciences, Inc., USA
Title: Development of the VesiculoVax™ vaccine platform to rapidly respond to new epidemic diseases
Marie-Claire Gauduin, Texas Biomedical Research Institute, USA
Title: Efficacy of Novel Epithelial Stem Cell-based AIDS Vaccine to Induce Mucosal Immune Responses and Protect against SIV Challenge in Macaques
Caroline T Tiemessen, University of the Witwatersrand, South Africa
Title: Host genetic variability and HIV vaccines: a focus on low affinity Fcγ receptors
Marc Van Regenmortel, University of Strasbourg, France
Title: Developing a preventive HIV vaccine requires solving inverse problems which is not feasible by rational vaccine design